You are here

Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease

Last updated on October 14, 2019

FOR MORE INFORMATION
Study Location
Mental Health Research Center of Russian Academy of Medical Sciences
Moscow, , Russian Federation
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Alzheimer's Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
50 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Males or females greater than or equal to 50 years of age.

2. Diagnosis of Alzheimer's Disease according to Diagnostic and Statistical Manual of
Mental Disorders, Fourth Edition, Text Revision (DSM-IV TR) and Mini Mental State Exam
between 10 and 24, inclusive and Modified Hachinski Ischemia Score less than or equal
to 4.

3. Brain imaging such as MRI and/or CT within one year of enrollment.

4. Subjects must have a guardian or caregiver who assists the subject at least 5 days per
week (at least 3 hours/day).

5. Subjects must be able to cooperate with drug administration (including the ability to
ingest oral medications) and study procedures and abide by study restrictions.

6. Subjects must have at least 6 years of prior education and should have previously (in
pre-Alzheimer's condition) been capable of reading, writing and communicating
effectively with others.

7. Subjects must be willing and able to give informed consent or have a mentally
competent legal representative authorized to provide informed consent on their behalf.

8. Residence in an assisted care facility is allowed if subject is living independently.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. Major structural brain disease

2. Major medical illness or unstable medical condition within 6 months of screening that
may interfere with the subject's ability to comply with study procedures and abide by
study restrictions.

3. Residence in a nursing home or assisted care facility that provides the subject with
24-hour care and supervision.

4. Women who are pregnant, nursing, or if of child-bearing potential not using a
medically accepted, highly effective method of birth control.

5. Active alcohol dependence or drug abuse.

6. Use of the following medications within 60 days prior to enrollment:cognition
enhancing agents, narcotic analgesics, low potency neuroleptics, antihypertensive
agents with frequent Central Nervous System (CNS) side effects, anti-Parkinsonian
medications, medications with central anticholinergic activity, medications for
epilepsy, lithium.

7. Participation in an investigational drug or device study within 30 days prior to study
entry, or 60 days prior to study entry if the investigational drug study involved
therapy for Alzheimer's Disease.

NCT00377715
Pfizer
Completed
Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Descriptive Information
Brief Title  ICMJE Double-blind, Placebo-controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease
Official Title  ICMJE Phase 2, Double-Blind, Placebo-Controlled Study of Oral Dimebon in Subjects With Mild to Moderate Alzheimer's Disease
Brief SummaryThis study will evaluate the safety and potential benefit of Dimebon as compared to placebo in patients with mild to moderate Alzheimer's Disease.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Condition  ICMJE Alzheimer's Disease
Intervention  ICMJE
  • Drug: Dimebon
  • Drug: Placebo
Study Arms  ICMJE
  • Experimental: Dimebon
    Dimebon 20 mg three times a day x 26 weeks
    Intervention: Drug: Dimebon
  • Placebo Comparator: Placebo
    Placebo 20 mg three times a day x 26 weeks
    Intervention: Drug: Placebo
Publications *Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D; dimebon investigators. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet. 2008 Jul 19;372(9634):207-15. doi: 10.1016/S0140-6736(08)61074-0.


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: December 26, 2007)
183
Original Enrollment  ICMJE
 (submitted: September 15, 2006)
166
Study Completion Date  ICMJE Not Provided
Actual Primary Completion DateAugust 2006   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  1. Males or females greater than or equal to 50 years of age.
  2. Diagnosis of Alzheimer's Disease according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV TR) and Mini Mental State Exam between 10 and 24, inclusive and Modified Hachinski Ischemia Score less than or equal to 4.
  3. Brain imaging such as MRI and/or CT within one year of enrollment.
  4. Subjects must have a guardian or caregiver who assists the subject at least 5 days per week (at least 3 hours/day).
  5. Subjects must be able to cooperate with drug administration (including the ability to ingest oral medications) and study procedures and abide by study restrictions.
  6. Subjects must have at least 6 years of prior education and should have previously (in pre-Alzheimer's condition) been capable of reading, writing and communicating effectively with others.
  7. Subjects must be willing and able to give informed consent or have a mentally competent legal representative authorized to provide informed consent on their behalf.
  8. Residence in an assisted care facility is allowed if subject is living independently.

Exclusion Criteria:

  1. Major structural brain disease
  2. Major medical illness or unstable medical condition within 6 months of screening that may interfere with the subject's ability to comply with study procedures and abide by study restrictions.
  3. Residence in a nursing home or assisted care facility that provides the subject with 24-hour care and supervision.
  4. Women who are pregnant, nursing, or if of child-bearing potential not using a medically accepted, highly effective method of birth control.
  5. Active alcohol dependence or drug abuse.
  6. Use of the following medications within 60 days prior to enrollment:cognition enhancing agents, narcotic analgesics, low potency neuroleptics, antihypertensive agents with frequent Central Nervous System (CNS) side effects, anti-Parkinsonian medications, medications with central anticholinergic activity, medications for epilepsy, lithium.
  7. Participation in an investigational drug or device study within 30 days prior to study entry, or 60 days prior to study entry if the investigational drug study involved therapy for Alzheimer's Disease.
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 50 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Russian Federation
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT00377715
Other Study ID Numbers  ICMJE DIM02
Has Data Monitoring CommitteeNot Provided
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyMedivation, Inc.
Study Sponsor  ICMJE Medivation, Inc.
Collaborators  ICMJE Not Provided
Investigators  ICMJE Not Provided
PRS AccountMedivation, Inc.
Verification DateNovember 2015

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now